Zivo Bioscience Business Summary

Zivo Bioscience, Inc. (ZIVO) is a research and development company operating at the intersection of biotechnology and agtech, primarily generating revenue through the licensing and sale of proprietary bioactive ingredients and algal biomass. The company’s business model centers on a dual-market strategy targeting Animal Health and Human Health segments, with a focus on high-value applications such as poultry feed additives for coccidiosis, bovine mastitis treatments, and human immune-modulating functional foods. Zivo leverages an extensive intellectual property portfolio of proprietary algal strains and fermentation processes to provide antibiotic-free, sustainable alternatives to traditional chemical therapeutics. In the competitive landscape, Zivo operates alongside specialized algal biotech firms like Fermentalg and Microphyt, as well as broader agtech players such as Advanced Enzyme Technologies and Cargill; it distinguishes itself by focusing on precision bioactive molecules rather than bulk biomass production. The leadership team is anchored by President, CEO, and Chairman John B. Payne, a veteran of the animal health industry who previously served as a member of the Global Leadership Team for Mars Pet Care and as CEO of Banfield Pet Hospitals. Supporting the executive suite is Interim CFO William A. Sullivan, who brings over 30 years of corporate finance experience from life sciences firms including Applied Genetic Technologies and Merrimack Pharmaceuticals, and Director of R&D Dr. Amy Steffek, a neuroscientist with extensive translational medicine expertise. The company’s strategic direction is further influenced by a board of directors and significant investors that include Christopher D. Maggiore, a major shareholder and director, and Strome Investment Management LP, which maintains a 10% ownership stake. Other notable board members include Lead Independent Director Alison Cornell, CFO of NVA Compassion-First, and Laith Yaldoo, managing member of HEP Investments LLC.